[{"address1": "Ugland House", "address2": "PO Box 309", "city": "Grand Cayman", "zip": "KY1-1104", "country": "Cayman Islands", "phone": "848 230 7430", "website": "https://www.adlainortye.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.", "fullTimeEmployees": 123, "companyOfficers": [{"maxAge": 1, "name": "Mr. Yang  Lu", "age": 44, "title": "Co- Founder, CEO & Chairman", "yearBorn": 1981, "exercisedValue": 0, "unexercisedValue": 0}], "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 10.14, "open": 10.14, "dayLow": 9.13, "dayHigh": 10.14, "regularMarketPreviousClose": 10.14, "regularMarketOpen": 10.14, "regularMarketDayLow": 9.13, "regularMarketDayHigh": 10.14, "payoutRatio": 0.0, "beta": -1.878, "forwardPE": -31.777779, "volume": 409801, "regularMarketVolume": 409801, "averageVolume": 876053, "averageVolume10days": 2613950, "averageDailyVolume10Day": 2613950, "bid": 10.28, "ask": 10.37, "bidSize": 4, "askSize": 2, "marketCap": 369371680, "fiftyTwoWeekLow": 0.879, "fiftyTwoWeekHigh": 12.09, "allTimeHigh": 19.3, "allTimeLow": 0.879, "fiftyDayAverage": 2.5728, "twoHundredDayAverage": 1.88998, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1108536960, "profitMargins": 0.0, "floatShares": 66714945, "sharesOutstanding": 31236934, "sharesShort": 135611, "sharesShortPriorMonth": 4639, "sharesShortPreviousMonthDate": 1765756800, "dateShortInterest": 1768435200, "sharesPercentSharesOut": 0.0037, "heldPercentInsiders": 0.0859, "heldPercentInstitutions": 0.00042, "shortRatio": 0.12, "shortPercentOfFloat": 0.0044, "impliedSharesOutstanding": 36900268, "bookValue": 0.215, "priceToBook": 46.55814, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -42592000, "trailingEps": -1.14, "forwardEps": -0.315, "enterpriseToEbitda": -26.466, "52WeekChange": 4.044776, "SandP52WeekChange": 0.120657206, "quoteType": "EQUITY", "currentPrice": 10.01, "targetHighPrice": 46.0, "targetLowPrice": 46.0, "targetMeanPrice": 46.0, "targetMedianPrice": 46.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 44145000, "totalCashPerShare": 0.399, "ebitda": -41885000, "totalDebt": 44567000, "quickRatio": 0.691, "currentRatio": 1.025, "debtToEquity": 562.644, "revenuePerShare": 0.061, "returnOnAssets": -0.29808, "returnOnEquity": -1.38983, "freeCashflow": -37974124, "operatingCashflow": -38569000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ANL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1770425381, "regularMarketTime": 1770411603, "exchange": "NGM", "messageBoardId": "finmb_1830112145", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "shortName": "Adlai Nortye Ltd.", "longName": "Adlai Nortye Ltd.", "regularMarketChangePercent": -1.28205, "regularMarketPrice": 10.01, "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1695994200000, "postMarketChangePercent": 1.2987024, "postMarketPrice": 10.14, "postMarketChange": 0.13000011, "regularMarketChange": -0.13, "regularMarketDayRange": "9.13 - 10.14", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 876053, "fiftyTwoWeekLowChange": 9.1310005, "fiftyTwoWeekLowChangePercent": 10.387941, "fiftyTwoWeekRange": "0.879 - 12.09", "fiftyTwoWeekHighChange": -2.08, "fiftyTwoWeekHighChangePercent": -0.172043, "fiftyTwoWeekChangePercent": 404.4776, "earningsTimestampStart": 1754650740, "earningsTimestampEnd": 1755864000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.14, "epsForward": -0.315, "epsCurrentYear": -0.17, "priceEpsCurrentYear": -58.882355, "fiftyDayAverageChange": 7.4372005, "fiftyDayAverageChangePercent": 2.890703, "twoHundredDayAverageChange": 8.12002, "twoHundredDayAverageChangePercent": 4.2963524, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2023-09-29", "averageAnalystRating": "2.0 - Buy", "cryptoTradeable": false, "displayName": "Adlai Nortye", "trailingPegRatio": null, "__fetch_time": "2026-02-07"}]